[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 24th that it has completed administration of the COVID-19 DNA vaccine GLS-5310 as a booster vaccine to the first three clinical trial subjects in the United States who had previously received mRNA vaccines and adenovirus vector vaccines.
The clinical trial is being conducted at three institutions in the United States to evaluate both intradermal (ID) and intranasal (IN) administration of GLS-5310. Intranasal administration is a very important method that induces mucosal immune responses to prevent COVID-19 virus infection and is evaluated through the formation of IgA antibodies responsible for immunity in the nasal mucosa.
A company official stated, “GLS-5310 includes not only the COVID-19 spike antigen but also the ORF3a antigen, which is important for viral replication and pathogenesis. Animal studies have already shown that intradermal administration of GLS-5310 using the Gene-Derm suction pressure delivery device elicited a strong immune response without skin tissue damage.”
He continued, “In the hamster challenge infection study conducted last October, it was confirmed that GLS-5310 completely prevented viral infection not only from the wild-type strain of the COVID-19 virus but also from the Beta variant. Additionally, binding inhibition studies confirmed that neutralizing antibodies against the wild-type strain were continuously produced, and although neutralizing antibodies were not detected against the Beta variant, complete prevention was still observed against the Beta variant.”
Park Younggeun, CEO of GeneOne Life Science, emphasized, “This study is a key milestone for the GLS-5310 vaccine in responding to the globally spreading COVID-19 virus. Administering GLS-5310 as a booster vaccine once again to individuals previously vaccinated against COVID-19 is a very important step to increase the vaccine’s utility by providing protection against the virus.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
